A new study, in collaboration with various international institutions, explores the role of glycans in cancer, focusing on the sTn marker, present in several types of tumors. These findings, published...
Read moreUn equipo de investigación del ICO, IDIBELL y Hospital de Bellvitge ha realizado un ensayo clínico aleatorizado en pacientes hematológicos con neutropenia febril para valorar la eficacia de la perf...
Read moreLos resultados del estudio de fase III PATINA, coordinado por SOLTI en España y Portugal, demuestran que añadir palbociclib como terapia de mantenimiento mejora la supervivencia libre de enfermedad ...
Read moreThe study has allowed identify a new strain of Helicobacter pylori which can be key to deepening the mechanisms that trigger this type of cancer. In addition, it will facilitate the development of new...
Read moreRecently published in The New England Journal of Medicine1 results of a phase 3, double-blind, randomized trial show that the addition of inavolisib to the combination of palbociclib and fulvestrant l...
Read moreA team from Clínic-IDIBAPS has introduced a modification to a CAR-T immunotherapy for multiple myeloma that makes it more durable, according to results obtained in animal and cellular models.
Read moreIt has been presented the phase I/II clinical trial of the HSP-CAR30 treatment for patients with refractory or relapsed Hodgkin lymphoma and CD30+ T-cell lymphoma. This innovative cellular therapy, a ...
Read moreThe probe reaches deep into the brain without causing appreciable damage, making it minimally invasive. It projects an ultra-thin beam of light.
Read moreLed by Thierry Andre, Head of the Department of Medical Oncology at the Hôpital Saint Antoine in Paris, the phase 3 open-label Checkmate 8HW trial evaluated first-line immunotherapy with nivolumab pl...
Read moreEste resultado es fruto de un trabajo de investigación, en el marco del Proyecto Soludable, sobre la incidencia de la radiación UV en participantes durante la prueba Ultra de Sierra Nevada 2023
Read moreThe journal The Lancet has published the results of a phase III clinical trial led by Josep Maria Llovet, from IDIBAPS-Hospital Clínic Barcelona. Involving 137 centres around the world, the trial mar...
Read more